TY - JOUR
T1 - The association of circulating adiponectin levels with pancreatic cancer risk; a study within the prospective EPIC cohort
AU - Grote, Verena A
AU - Rohrmann, Sabine
AU - Nieters, Alexandra
AU - Dossus, Laure
AU - Halkjaer, Jytte
AU - Tjønneland, Anne
AU - Overvad, Kim
AU - Stegger, Jakob
AU - Chabbert-Buffet, Nathalie
AU - Boutron-Ruault, Marie-Christine
AU - Clavel-Chapelon, Françoise
AU - Teucher, Birgit
AU - Becker, Susen
AU - Montonen, Jukka
AU - Boeing, Heiner
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Trichopoulos, Dimitrios
AU - Palli, Domenico
AU - Sieri, Sabina
AU - Tumino, Rosario
AU - Vineis, Paolo
AU - Mattiello, Amalia
AU - Argüelles, Marcial
AU - Duell, Eric J
AU - Molina-Montes, Esther
AU - Larrañaga, Nerea
AU - Chirlaque, María-Dolores
AU - Gurrea, Aurelio Barricarte
AU - Jeurnink, Suzanne M
AU - Peeters, Petra Hm
AU - Ye, Weimin
AU - Sund, Malin
AU - Lindkvist, Björn
AU - Johansen, Dorthe
AU - Khaw, Kay-Tee
AU - Wareham, Nick
AU - Crowe, Francesca L
AU - Romieu, Isabelle
AU - Rinaldi, Sabina
AU - Jenab, Mazda
AU - Romaguera, Dora
AU - Michaud, Dominique S
AU - Riboli, Elio
AU - Bueno-de-Mesquita, H Bas
AU - Kaaks, Rudolf
N1 - Copyright © 2011 Wiley-Liss, Inc.
PY - 2012
Y1 - 2012
N2 - Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e. decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a case-control study nested within EPIC. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.23-0.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.67-3.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development. © 2011 Wiley-Liss, Inc.
AB - Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e. decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a case-control study nested within EPIC. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.23-0.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.67-3.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development. © 2011 Wiley-Liss, Inc.
U2 - 10.1002/ijc.26244
DO - 10.1002/ijc.26244
M3 - Journal article
SN - 0020-7136
VL - 130
SP - 2428
EP - 2437
JO - International Journal of Cancer
JF - International Journal of Cancer
ER -